Immorta Bio, Inc
Biotechnology company focused on developing personalized cellular therapeutics and senescence-targeting immunotherapies to address age-related diseases and organ failure. The company advances ex vivo cell reprogramming and autologous progenitor/mesenchymal cell platforms, conducts preclinical in vivo testing across oncology and organ-failure models, and maintains a growing patent portfolio supporting clinical translation and regulatory filings.
Industries
N/A
Nr. of Employees
small (1-50)
Immorta Bio, Inc
Mailing: 7064 Fisher Island Drive, Miami Beach, FL 33109; Office: 19505 Biscayne Blvd, Ste 2350, Aventura, FL 33180
Products
Senolytic immunotherapy (dendritic cell vaccine targeting senescent cells)
Preclinical immunotherapy designed to stimulate immune clearance of senescent cells in the tumor microenvironment and other age-related pathologies; demonstrated tumor regression and immune activation in animal studies.
Personalized progenitor and regenerative cell platform (autologous organ-specific cells)
Platform for creating patient-derived reprogrammed cells and differentiating them into organ-specific progenitors and mesenchymal cell products for tissue repair and organ rejuvenation; preclinical data reported in liver failure models.
Senolytic immunotherapy (dendritic cell vaccine targeting senescent cells)
Preclinical immunotherapy designed to stimulate immune clearance of senescent cells in the tumor microenvironment and other age-related pathologies; demonstrated tumor regression and immune activation in animal studies.
Personalized progenitor and regenerative cell platform (autologous organ-specific cells)
Platform for creating patient-derived reprogrammed cells and differentiating them into organ-specific progenitors and mesenchymal cell products for tissue repair and organ rejuvenation; preclinical data reported in liver failure models.
Expertise Areas
- Senolytic immunotherapy
- Personalized stem cell and progenitor cell therapies
- Preclinical in vivo study design and execution
- Immuno-oncology
Key Technologies
- Cell reprogramming to pluripotent-like states
- Autologous mesenchymal and progenitor cell generation
- Dendritic cell-based vaccine platforms
- Exosome/secretome therapeutics
News & Updates
Company presentation providing updates on senolytic immunotherapy and personalized cell platforms.
Selected to present preclinical senolytic immunotherapy data at the American Association of Immunologists Annual Meeting.
Publication reporting preclinical data showing that a senescence-targeting immunotherapy eliminated senescent cells and produced tumor regression in murine lung cancer models.
Interview with the company's CSO discussing focus on aging-related diseases, pipeline priorities (liver failure and lung cancer), and IND plans.
Public statement that 23 priority patent applications covering senescence science and regenerative medicine were filed since 2022.
Filed patent and preclinical data reporting that a patient-derived mesenchymal stem cell product preserved liver function in a carbon tetrachloride animal model.
Company presentation providing updates on senolytic immunotherapy and personalized cell platforms.
Selected to present preclinical senolytic immunotherapy data at the American Association of Immunologists Annual Meeting.
Publication reporting preclinical data showing that a senescence-targeting immunotherapy eliminated senescent cells and produced tumor regression in murine lung cancer models.
Interview with the company's CSO discussing focus on aging-related diseases, pipeline priorities (liver failure and lung cancer), and IND plans.
Public statement that 23 priority patent applications covering senescence science and regenerative medicine were filed since 2022.
Filed patent and preclinical data reporting that a patient-derived mesenchymal stem cell product preserved liver function in a carbon tetrachloride animal model.